The deal size was increased to $125M in common stock from $100M in common stock. Jefferies, Leerink and Goldman Sachs acted as joint book running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
- Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
- Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
- Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
- Viridian announces REVEAL-2 phase 3 study met primary endpoint